169 results about "Pioglitazone" patented technology

Provided herein are drug products with low dose pioglitazone for use in the treatment (e.g., delay of onset) of cognitive impairment of the Alzheimer's type. Methods of manufacture thereof are also provided. Further provided are methods of treatment for Alzheimer's disease including administering a drug product with low dose pioglitazone. The methods may include determining whether the subject is at risk of developing Alzheimer's disease based upon the subject's age and TOMM40 523 genotype.

A slow-releasing capsule of compound fluamine pyrrolinone for treating diabetes is composed of the central slow-releasing fluamine microball or small tablet and the coated fast-releasing pyrrolinone layer. Its advantages are high curative effect and no toxic by-effect.

A novel process for preparing thiazolidinediones, preferably Pioglitazone, as described. Also described are novel intermediates involved in its synthesis and process for their preparation and use in medicine.

The invention relates to the field of medicine, and discloses a culture medium for inducing adipogenic differentiation of muscle derived stem cells of skeletal muscles, and an application and an adipogenic differentiation method thereof. The culture medium disclosed by the invention comprises 3-isobutyl-1-methylxanthine, insulin, indomethacin, dexamethasone, pioglitazone and FBS in a basic culture medium. The components of the culture medium are optimized and are induced to differentiate, and the conventional component in the existing mesenchymal stem cells is replaced by pioglitazone, so that an effect of significantly improving the adipogenic differentiation rate of the muscle derived stem cells of skeletal muscles is realized.

The present invention provides pioglitazone of defined particle size distribution. The Pioglitazone of defined particle size can be formulated into a wide variety of dosage forms.

The present invention relates to a method and composition for use in treating a condition that benefits from the reduction of hepatic and/or visceral fat, such as polycystic ovary syndrome in adolescent girls or women of childbearing age, involving the use of spironolactone, pioglitazone and metformin.

The invention relates to a detection method for qualitatively detecting whether thiazolidinedione medicines are doped in a Chinese patent medicine and a health food which have a hypoglycemic effect. The method comprises the following steps: 1, taking a sample to be measured, adding dichloromethane according to a case that 5-10mL of dichloromethane corresponds with 1g of the sample, strongly shaking for at least 40s, and filtering; 2, adding a small amount of a hydrochloric acid solution with the concentration of 0.08-0.12mol/L to a filtrate obtained in step 1, up-down overturning at least eight times, and standing for two-phase layering; and 3, adding a proper amount of a phosphomolybdic acid solution with the concentration of 0.04-0.1g/mL to an upper layer obtained in step 2 drop by drop. If deposition or turbidity appears, it shows that rosiglitazone or pioglitazone is doped in the sample. A corresponding kit comprises a reagent 1: dichloromethane; a reagent 2: the hydrochloric acid solution with the concentration of 0.08-0.12mol/L; and a reagent 3: the phosphomolybdic acid solution with the concentration of 0.04-0.1g/mL. The detection method of the invention has the advantages of accuracy and reliability, and the kit is convenient for carrying and carrying out onsite detection.

The invention relates to the application of pioglitazone and heparin or low molecular heparin or pharmaceutically acceptable salts thereof or derivatives thereof to preparing a pharmaceutical composition, in particular to the application to preparing a medicament for preventing or treating fatty liver. the purpose of the pioglitazone and the heparin or the low molecular heparin or the pharmaceutically acceptable salts thereof in lessening fat deposition in rat hepatocytes and the synergy of a pioglitazone and heparin or low molecular heparin compound in preventing or treating the rat fatty liver are proved by animal tests. The invention provides a new candidate medicament for searching a medicament for lessening fat deposition in hepatocytes and treating diseases caused by clinic lipid metabolism, such as fatty liver, and the like and therefore enriches the prior art.

A compound of the formula:

wherein A represents a ring group connected to the oxygen atom by a C₁ to C₆ hydrocarbon chain, R is hydrogen or a C₁-C₄ alkyl, and Q is hydrogen, or an amine protecting group such as acetyl, trifluoroacetyl, benzoyl, benzyl, or trityl, is useful in making thiazolidinedione derivatives

such as pioglitazone, rosiglitazone and troglitazone.

Provided is a novel crystal form of pioglitazone hydrochloride and a method for making it. Also provided is a method for making a known crystal form of pioglitazone hydrochloride.

The invention discloses a qualitative analysis detection method for illegally mixed high-polar chemical anti-diabetic components in anti-diabetic traditional Chinese medicine products. The method comprises the following steps that: 1) high efficient liquid phase chromatography conditions: an ammonium acetate-triethylamine-acetonitrile moving phase system and a C18 chromatographic column with certain specification are used, the wavelength is detected by ultraviolet, and the flow rate is 1.0ml/min; 2) analysis result: glibenclamide, glipizide, gliclazide, glimepiride, gliquidone, repaglinide, nateglinide, rosiglitazone and pioglitazone hydrochloride can realize the complete separation; 3) result judgment: when retention time of a chromatographic peak in an anti-diabetic traditional Chinese medicine product is consistent with that of anti-diabetic medicine in the step 2) and the apparent absorption is shown out, which indicate that the anti-diabetic medicine is contained in the sample to be tested. The method has the advantages of quickness, simplicity, convenience, high sensitivity, strong specialization, broad coverage and so on.

The invention discloses a pharmaceutical composition for treating diabetes and complication thereof, and particularly relates to a composition containing arctigenin and PioglitaZone or pharmaceutically acceptable salts thereof and to the purpose of the composition in preparing medicines for treating diabetes, diabetic complication and diseases related to diabetes.

An improved process for the preparation of pioglitazone and its pharmaceutically acceptable salts by reducing 5-[4-[2-(5-ethyl-2-pyridyl)ethoxy]benzilidene]-2,4-thiazolidinedione with sodium borohydride in presence of a cobalt ion and dimethyl glyoxime. More particularly the cobalt ion used is cobalt chloride hexahydrate, or, cobalt (II) nitrate hexahydrate in presence of mixture of DMF and water as solvents.

The invention discloses a pioglitazone hydrochloride solid dispersoid and a medicinal compounds thereof as well as preparation methods and applications thereof. The pioglitazone hydrochloride solid dispersoid contains pioglitazone hydrochloride and PEG6000, with the weight ratio of 1:1. 5-9. The preparation method of the pioglitazone hydrochloride solid dispersoid comprises the following steps: A1. heating the PEG6000 to 60-80 DEG C, so as to enable the PEG6000 to be in a liquid state; A2. under the condition of constantly stirring the solution, adding the pioglitazone hydrochloride with proportional amount, stirring and dispersing for 20-40 minutes; and A3. quickly pouring a mixture on a metal panel with fast heat conduction to form a thin solid layer, immediately placing the thin solid layer in an environment with temperature below -20 DEG C, quenching for 50-70 minutes, taking out, smashing and screening with a 100-mesh sieve. The invention has the beneficial effects that the solid dispersoid can greatly improve the dissolution rate of the pioglitazone hydrochloride in a dissolution medium, so as to increase bioavailability. A solid dispersing agent can be further made into the medicinal compounds in forms of tablets and capsules.

The invention provides application of 5-arylmethylenethiazolidine-2,4-dione shown as the general formula I and 5-heterocyclemethylenethiazolidine-2,4-dione shown as the general formula II in preparation of a PPAR (Peroxisome Proliferator Activated Receptor) agonist, wherein 5-arylmethylenethiazolidine-2,4-dione and 5-heterocyclemethylene-thiazolidine-2,4-dione both has PPAR agonistic activity, the relative agonist ratio of a part of compounds to pioglitazone which is an existing PPARgamma agonist is higher than 100% and can be 239.77% at most, and therefore the part of compounds can be developed into high-efficiency low-toxicity antidiabetic drug possibly or can be used as antidiabetic leading molecules to be applied to the further structural optimization.